Clinical trials
Immune System Diseases trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Completed | 7 |
| Active, not recruiting | 4 |
| Terminated | 3 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cogent Biosciences, Inc. | 2 |
| Ellodi Pharmaceuticals, LP | 2 |
| Novartis Pharmaceuticals | 2 |
| Takeda | 2 |
| Aravax Pty Ltd | 1 |
| Ariad Pharmaceuticals | 1 |
| AstraZeneca | 1 |
| Beeline Medicines Corporation | 1 |
| Bristol-Myers Squibb | 1 |
| Eli Lilly and Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immune System Diseases | 25 |
| Autoimmune Diseases | 11 |
| Hematologic Diseases | 9 |
| Connective Tissue Diseases | 5 |
| Hypersensitivity | 5 |
| Neoplasms | 4 |
| Skin Diseases | 4 |
| Blood Platelet Disorders | 3 |
| Glomerulonephritis | 3 |
| Glomerulonephritis, IGA | 3 |
Trials
Showing 76 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.